These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35373021)

  • 61. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
    Tao X; Zhang H; Yang Y; Zhang C; Wang M
    Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of Individualized Dietary Phosphate Control Program With a Smartphone Application in Hemodialysis Patients in Taiwan.
    Chiang YC; Chang YP; Lin SC; Lin C; Hsu PH; Hsu YJ; Wu TJ
    Biol Res Nurs; 2021 Jul; 23(3):375-381. PubMed ID: 33251815
    [TBL] [Abstract][Full Text] [Related]  

  • 65. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Hyperphosphatemia in dialysis: which binder?].
    Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
    Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patient empowerment in the management of hyperphosphatemia.
    Kuhlmann MK; Hoechst S; Landthaler I
    Int J Artif Organs; 2007 Nov; 30(11):1008-13. PubMed ID: 18067103
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2022 Dec; 26(12):1223-1232. PubMed ID: 36064876
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
    Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
    Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
    Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
    Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A bundled phosphate control intervention (4Ds) for adults with end-stage kidney disease receiving haemodialysis: A cluster randomized controlled trial.
    Milazi M; Douglas C; Bonner A
    J Adv Nurs; 2021 Mar; 77(3):1345-1356. PubMed ID: 33277736
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
    Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
    Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
    Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
    Weinreich T; Passlick-Deetjen J; Ritz E
    Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.